Ubs Group Ag Arcus Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 85,896 shares of RCUS stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,896

Previous 75,113 14.36%

Holding current value

$1.31 Million

Previous $1.14 Million 14.87%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $147,619 - $194,201	10,783 Added 14.36%	85,896 $1.31 Million
Q2 2024 Aug 13, 2024	SELL	$14.59 - $18.48 $1.95 Million - $2.47 Million	-133,616 Reduced 64.01%	75,113 $1.14 Million
Q1 2024 May 13, 2024	BUY	$14.83 - $20.18 $685,813 - $933,224	46,245 Added 28.46%	208,729 $3.94 Million
Q4 2023 Feb 09, 2024	BUY	$13.43 - $19.63 $1.41 Million - $2.06 Million	104,947 Added 182.4%	162,484 $3.1 Million
Q3 2023 Nov 09, 2023	SELL	$17.62 - $23.54 $735,758 - $982,959	-41,757 Reduced 42.05%	57,537 $1.03 Million
Q2 2023 Aug 11, 2023	BUY	$16.97 - $22.03 $10,809 - $14,033	637 Added 0.65%	99,294 $2.02 Million
Q1 2023 May 12, 2023	BUY	$15.96 - $23.15 $620,987 - $900,743	38,909 Added 65.12%	98,657 $1.8 Million
Q4 2022 Feb 08, 2023	BUY	$19.7 - $35.71 $395,024 - $716,056	20,052 Added 50.51%	59,748 $1.24 Million
Q3 2022 Nov 10, 2022	SELL	$23.23 - $30.07 $891,613 - $1.15 Million	-38,382 Reduced 49.16%	39,696 $1.04 Million
Q2 2022 Aug 10, 2022	SELL	$17.23 - $37.73 $2 Million - $4.37 Million	-115,801 Reduced 59.73%	78,078 $1.98 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $5.44 Million - $7.87 Million	188,069 Added 3236.99%	193,879 $6.12 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $475,281 - $734,126	-15,146 Reduced 72.28%	5,810 $235,000
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $374,165 - $523,525	13,894 Added 196.74%	20,956 $731,000
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $872,508 - $1.37 Million	-38,352 Reduced 84.45%	7,062 $194,000
Q1 2021 May 12, 2021	BUY	$26.16 - $41.39 $1.18 Million - $1.86 Million	45,043 Added 12140.97%	45,414 $1.28 Million
Q4 2020 Feb 11, 2021	BUY	$17.0 - $32.36 $6,307 - $12,005	371 New	371 $10,000
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $63,983 - $95,079	-3,733 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$13.97 - $36.56 $242,016 - $633,365	-17,324 Reduced 82.27%	3,733 $92,000
Q1 2020 May 01, 2020	SELL	$8.78 - $19.28 $191,526 - $420,573	-21,814 Reduced 50.88%	21,057 $292,000
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $132,233 - $194,651	18,040 Added 72.65%	42,871 $433,000
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $122,720 - $193,990	19,056 Added 329.97%	24,831 $226,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $42,099 - $77,269	5,775 New	5,775 $46,000
Q1 2019 May 14, 2019	SELL	$8.95 - $12.49 $120,511 - $168,177	-13,465 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$9.74 - $14.5 $108,961 - $162,211	11,187 Added 491.09%	13,465 $145,000
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.95 $18,202 - $25,011	1,673 Added 276.53%	2,278 $32,000
Q2 2018 Aug 14, 2018	BUY	$12.24 - $17.05 $7,405 - $10,315	605 New	605 $7,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account